摘要
目的回顾性分析我国近20年胺碘酮在临床的使用情况,探讨其不良反应(ADR)发生的临床特点、产生原因及预防措施,并评价胺碘酮在治疗心律失常疾病中的利益与风险。方法利用《中文科技期刊数据库》收集临床资料,按照设定的标准,用SPSS 11.5软件进行统计分析,并对药品利益-风险进行半定量分析。结果共获得113篇可用的相关文献,共计有5806个临床病例参加安全性评价,发生ADR计1384例次。ADR涉及心血管系统、消化系统、甲状腺系统、皮肤、神经系统、呼吸系统、眼部等多个系统和器官,且有4例致死、4例晕厥的严重ADR病例报告。结论利益-风险分析表明胺碘酮对心律失常的治疗效果较好,但其ADR不容忽视,窦性心动过缓,低血压、甲状腺异常、肺纤维化是常见的ADR。其中,肺损害是胺碘酮的主要ADR之一。
Objective We retrospectively analyzed the usage of amiodarone in the past 20 years in China, to investigate clinical features and adverse drug reaction （ADR） and measures of avoidance; to evaluate the benefit and risk of amiodarone in the treatment of arrhythnlia. Method Clinical databases were collected through ＂The Chinese technological periodical base＂, and analyzed by SPSS11.5 software according to the common criteria. The benefit and risk of amiodarone were evaluated by means of systematic literature reviews. Result There were 113 related literatures altogether, including 5806 cases and 1384 ADR cases. ADR involved in many systems, such as cardiovascular system, digestive system , thyroid, skin, neurologic system, respiratory system, eye, and so on. Severe ADR were reported, including 4deaths and 4 syncopes. Conclusion The benefit and risk evaluation shows anfiodarone in treatment of arrhythmia has more effect than risk. but ADR can not neglected such as bradycardie, low blood pressure, thyroid dysfunction, pulmonary toxicity.
出处
《中国分子心脏病学杂志》
CAS
2007年第4期232-236,共5页
Molecular Cardiology of China
关键词
胺碘酮
药物安全性
利益-风险
不良反应
Amiodarone
Drug sefety
Benefit and risk
Adverse drug reaction
